Development and Validation of a Liquid Chromatography-Tandem Mass Spectrometry Method for Analysis of Riluzole in Human Plasma and Its Application on a Bioequivalence Study

Introduction. As the first approved drug for amyotrophic lateral sclerosis (ALS) treatment, riluzole is known as a glutamatergic neurotransmission inhibitor administrated in 50 mg tablets twice daily. For this reason, a generic product of riluzole has been developed at a lower price by Hogar-Daroo, Iran, which would benefit patients.

Aim. The objective of this study is to develop and validate a novel liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the analysis of riluzole in human plasma samples and its application in the bioequivalence study of riluzole tablet.

Materials and methods. The chromatography was performed by using a C18 column (100 mm, 4.6 mm, 5 mm), 0.1 % formic acid and acetonitrile (60 : 40, v/v) as the mobile phase, at a flow rate of 0.90 ml/min in the gradient program. Carbamazepine was used as an internal standard (IS). The method employed only 100 µL of human plasma for quantification by a liquid-liquid extraction technique. The multiple reaction monitoring modes (MRM) was used for quantification of ion transitions m/z 235.0/165.9 and m/z 137.6/110.0 for riluzole and the m/z 236.9/194.0 for the IS. Dwell time was set at 200 ms.

Results and discussion. The calibration curve was linear over the concentration range 0.5–300 ng/mL. The lower limit of quantitation (LLOQ) was obtained at 0.5 ng/mL. The intra-day and inter-day accuracy ranged from 93.21 % to 101.34 % and 91.77 % to 104.88 % respectively. The intra-day and inter-day precision values ranged from 2.19 % to 5.69 % and 1.67 % to 5.31 % respectively, all within the FDA acceptable ±15 %.

Conclusion. The validated method was applied in Iranian healthy subjects under fasting condition with a 50 mg riluzole tablet successfully.

1. Qiu Y., Chen Y., Zhang G., Yu L., Mantri R. V., editors. Developing solid oral dosage forms. 2 edition. Boston: Academic Press; 2017. P. 1127–1160.

2. Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996;47(6–4):S233–S241. DOI: 10.1212/wnl.47.6_suppl_4.233s.

3. Longinetti E., Fang F. Epidemiology of amyotrophic lateral sclerosis: An update of recent literature. Curr Opin Neurol. 2019;32(5):771–776. DOI: 10.1097/wco.0000000000000730.

4. Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur J Neurol. 2020;27(10):1918–1929. DOI: 10.1111/ene.14393.

5. Oskarsson B., Gendron T. F., Staff N. P. Amyotrophic lateral sclerosis: An update for 2018. Mayo Clin Proc. 2018;93(11):1617–1628. DOI: 10.1016/j.mayocp.2018.04.007.

6. Narapusetti A., Bethanabhatla S. S., Sockalingam A., Pilli N. R., Repakab N., Allaf T. Bioanalysis of riluzole in human plasma by a sensitive LC-MS/MS method and its application to a pharmacokinetic study in south indian subjects. Analytical Methods. 2014;6(13):4823–4830. DOI: 10.1039/C4AY00583J.

7. Vikram P., Shanmugasundaram P. Determination of riluzole in human plasma by ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and its application to a pharmacokinetic study. Research Journal of Pharmacy and Technology. 2017;10(1):193–199. DOI: 10.5958/0974-360X.2017.00042.7.

8. Chandu B. R., Nama S., Kanala K., Challa B. R., Shaik R. P., Khagga M. Quantitative estimation of riluzole in human plasma by LC-ESI-MS/MS and its application to a bioequivalence study. Anal Bioanal Chem. 2010;398(3):1367–1374. DOI: 10.1007/s00216-010-4034-8.

9. Zimmer D. New us fda draft guidance on bioanalytical method validation versus current fda and ema guidelines: Chromatographic methods and isr. Bioanalysis. 2014;6(1):13–19. DOI: 10.4155/bio.13.298.

10. Karpova P. A., Komarov T. N., Archakova O. A., Shchelgacheva D. S., Suvorova A. V., Bagaeva N. S., Karnakova P. K., Shohin I. E. Development and validation of a method for determining deferasirox in human blood plasma by HPLC-UV. Drug development and registration. 2022;11(2):187–196. DOI: 10.33380/2305-2066-2022-11-2-187-196.

11. Matuszewski B. K., Constanzer M. L., Chavez-Eng C. M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003;75(13):3019–3030. DOI: 10.1021/ac020361s.

12. Caban M., Migowska N., Stepnowski P., Kwiatkowski M., Kumirska J. Matrix effects and recovery calculations in analyses of pharmaceuticals based on the determination of β-blockers and β-agonists in environmental samples. Journal of Chromatography A. 2012;1258:117–127. DOI: 10.1016/j.chroma.2012.08.029.

13. Chow D. S., Teng Y., Toups E. G., Aarabi B., Harrop J. S., Shaffrey C. I., Johnson M. M., Boakye M., Frankowski R. F., Fehlings M. G., Grossman R. G. Pharmacology of riluzole in acute spinal cord injury. Journal of Neurosurgery: Spine. 2012;17(1):129–140. DOI: 10.3171/2012.5.Aospine12112.

14. Nagoshi N., Nakashima H., Fehlings M. G. Riluzole as a neuroprotective drug for spinal cord injury: From bench to bedside. Molecules. 2015;20(5):7775–7789. DOI: 10.3390/molecules20057775.

15. Wagner M. L., Landis B. E. Riluzole: A new agent for amyotrophic lateral sclerosis. Ann Pharmacother. 1997;31(6):738–744. DOI: 10.1177/106002809703100614.

16. Chow S. C. Bioavailability and bioequivalence in drug development. Wiley Interdisciplinary Reviews: Computational Statistics. 2014;6(4):304–312. DOI: 10.1002/wics.1310.

17. Mathew T. Bioequivalence studies in drug development: Methods and applications by dieter hauschke, volker steinijans, iris pigeot. International Statistical Review. 2007;75(2):272–273. DOI: 10.1111/j.1751-5823.2007.00015_24.x.